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herg (human eag related gene) encodes a particular type of K+
channel (HERG) belonging to an evolutionary conserved multi-
gene family of voltage-activated, outward rectifying K+ channels,
the eag (ether a-gò-gò) family (Warmke and Ganetzky, 1994). The
corresponding current (IHERG) is characterized by inward rectifica-
tion properties, and its role is well known in the heart, where it
contributes to the repolarization of the cardiac action potential
(Sanguinetti et al, 1995), and is being discovered in neurons,
where it appears to regulate spike-frequency adaptation (Chiesa 
et al, 1997). We first demonstrated that herg and its related current
are preferentially expressed in neoplastic cell lines of different
histogenesis (Arcangeli et al, 1993, 1995; Faravelli et al, 1996;
Bianchi et al, 1998); in tumour cells, IHERG is responsible for main-
taining substantially depolarized resting potentials, a recurrent
feature in cancer cells (Binggeli and Weinstein, 1986; Olivotto 
et al, 1996). Following this first discovery, another member of the
family, the EAG channel, has been found to be preferentially
expressed in tumour cell lines, and to confer oncogenic properties
to transfected cells (Pardo et al, 1999). On the whole, a functional
role in oncogenesis can be tentatively attributed to genes
belonging to the eag family of K+ channels. 
On these bases we have undertaken a study to evaluate herg
expression in primary human tumours, to be compared with the
correspondent normal or hyperplastic tissues. The endometrial
cancer (EC) was chosen for this purpose: in fact, besides being
nowadays the commonest invasive malignancy of the female
genital tract (Burton and Wells, 1998), the molecular pathogenesis
of EC is still largely unknown (Berchuck and Boyd, 1995), despite
the numerous genomic alterations so far reported, such as abnor-
malities of ploidy (Milatovich, 1990), instability of microsatellite
sequences (Risinger et al, 1993; Burks, 1994), altered expression
of various genes (reviewed by Burton and Wells, 1998; Baker,
1996). In this context, special attention has been given to point
mutations of the p53 tumour suppressor gene, leading to an over-
expression of mutant p53 protein (Porter et al, 1992; Koheler et al,
1993), expression of the oncogene bcl-2 (Taskin et al, 1997) and of
oestrogen and progesterone receptor (ER and PR) (Creasman,
1993). Despite these studies, no molecular marker is nowadays as
valuable in determining prognosis as conventional histopatholo-
gical parameters, in particular the histopathological grading. Thus,
the study of the molecular events underlying EC tumorigenesis, as
well as the determination of new, specific, molecular markers
characterizing EC are deeply encouraged, to help the pathologist
in the diagnostic and prognostic evaluation of EC. 
We present here a study showing that herg and HERG protein
are much more frequently expressed in EC as compared to 
non-cancerous (normal and/or hyperplastic) endometrium (NCE);
RT-PCR analysis has been performed in parallel with immuno-
histochemical assays, and patch clamp recordings: all techniques
lead to the same result that herg RNA and HERG protein
expression marks a high percentage of EC, as compared to 
NCE. 
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Summary HERG K+ channels, besides contributing to regulate cardiac and neuronal excitability, are preferentially expressed in tumour cell
lines of different histogenesis, where their role in the development and maintenance of the neoplastic phenotype is under study. We show
here that both herg gene and HERG protein are expressed with high frequency in primary human endometrial cancers, as compared to
normal and hyperplastic endometrium. RT-PCR and immunohistochemistry, using specific anti-HERG antibodies developed in our laboratory,
were applied to tissue specimens obtained from 18 endometrial cancers and 11 non-cancerous endometrial tissues. herg RNA and HERG
protein are expressed in 67% and 82%, respectively, of cancerous, while in only 18% of non-cancerous tissues. In particular, no expression
was found in endometrial hyperplasia. Moreover, electrophysiological experiments confirmed the presence of functioning HERG channels on
the plasma membrane of tumour cells. On the whole, these data are the first demonstration of the presence of HERG channels in primary
human neoplasias, and could candidate HERG as a potential tool capable of marking cancerous versus hyperplastic endometrial growth. 
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MATERIALS AND METHODS 
Tissue collection 
Surgical specimens were obtained from 28 women undergoing
hysterectomy for endometrial cancer (17 cases), for leiomyoma
uteri (5 cases), for prolapsus uteri (2 cases), for ovarian cystic
disease (2 cases) and for intractable methrorrhagia (2 cases). One
histological specimen of EC was obtained from endometrial
biopsy. Samples used for RT-PCR analysis were obtained from the
hysterectomy specimens after a gentle and superficial scraping of
the endometrial tissue, using a sterile curette, from fresh, non-
fixed uterine body, longitudinally cut. Endometrial tissue was in
any case immediately frozen; several histological frozen sections
obtained from a portion of the endometrial tissue were immedi-
ately examined in order to verify the absence of myometrium; 
the latter could in fact lead to ambiguous results (see Results); for
this reason, hypo/atrophic specimens, as well as all samples that
resulted contaminated, were excluded from our study and only
pure endometrial tissue was utilized for RT-PCR analysis.
Histological and immunohistochemical evaluations were per-
formed on uterine tissues routinely sampled and processed, 
from either hysterectomy specimens and endometrial biopsy
tissue. 
Gynaecological pathologists (GLT, AMB) using standard criteria
assessed the histological diagnosis. In 18 women, whose mean age
was 62 years (range 45–85 years), the diagnosis was an endometrial
cancer: among these, 11 cases were usual endometrioid adenocarci-
noma, 3 were adenocarcinoma with squamous metaplasia, 2 cases
were serous-papillary carcinoma, 1 secretory adenocarcinoma and
1 case was mesonephroid or clear cell adenocarcinoma. Four
patients had good differentiation (G1), 7 had intermediate (G2) 
and 5 poor differentiation (G3). For 2 serous-papillary carcinoma
grading was not performed, although they can be compared with
poorly differentiated, G3. Histological diagnosis in the remaining
11 women was proliferative endometrium (1 case), secretive
endometrium (4 cases), and simple endometrial hyperplasia
without atypia (6 cases). The median age was 47 years in women
with proliferative or secretive endometrium (range 42–54), and 56
years (range 49–75) in simple hyperplasia. 
Histological examinations and immunohistochemistry 
The histological study on endometrial samples was performed at
the Department of Pathology, University of Florence, Italy.
Endometrial specimens were routinely fixed in buffered formalin
and embedded in paraffin. The pathologists evaluated the endomet-
rial histology on sections stained with haematoxylin and eosin.
Several consecutive sections were used for immunohistochemical
study. Once the sections had been mounted on electrostatic slides
and air-dried overnight at 37˚C, they were deparaffinized through
xylene and rehydrated through a graded alcohol series. The
endogenous peroxidase activity was blocked by immersing the
specimens in a solution of 0.5% H2O2 in distilled water. To recover
antigenicity, slides were placed in 10 mM citrate buffer pH 6.0 and
heated in a household microwave oven at 300 W for 40 min. After
microwave processing, the sections were allowed to cool down for
20 min at room temperature, washed with phosphate buffered
saline solution (PBS, pH 7.4) and treated with normal horse serum
(LAB VISION Corporation Fremont, CA, USA) to reduce 
non-specific antibody binding. 
Several different primary antibodies were used: monoclonal
antibody 1D5 raised against human oestrogen receptor (1:30
dilution, Bio-Genex, San Ramon, CA, USA); monoclonal anti-
body 1A6 raised against human progesterone receptor (1:50
dilution, Bio-Genex); a murine monoclonal antibody IgG2
antibody DO-7 raised against human p53 (1:40 dilution, DAKO
A/S, Denmark), which reacts with wild type and mutant p53
protein and a murine monoclonal (clone 124, IgG1) anti-human
bcl-2 antibody (1:20 dilution, DAKO). After washing with PBS,
sections were incubated with biotinylated goat anti polyvalent
antibody (LAB VISION) and then with streptavidin-biotin-peroxi-
dase complex reagent (LAB VISION). After extensive washing
with PBS, slides were treated with 3,3′ -diaminobenzidine-
hydrogen peroxide (Bio-Genex), as the final indicator, and
counterstained lightly with Mayer’s haematoxylin. Negative
control experiments were performed by replacing the primary anti-
bodies with non-immune mouse serum at an equivalent protein
concentration. 
Histological sections were also treated with polyclonal anti-
HERG antibody (1:1000 dilution, obtained in Dr Arcangeli’s labor-
atory, see below), using the previously described standard method
of immunoperoxidase staining without microwave. Positive
control experiments of anti-HERG antibodies were performed on
sections relative to a human heart (explanted from a patient
suffering from cardiomyopathy), as well as on SY5Y neuroblas-
toma cell line, cultured in DMEM + 10% fetal calf serum (FCS) as
previously described (Arcangeli et al, 1995). In this case, cells
were cultured on a glass slide for 48 hours, then washed in PBS
and fixed in absolute ethanol for 10 min, then processed as above.
Negative control experiments were performed treating the histo-
logical sections with a non-immune rabbit serum (DAKO) instead
of the primary anti-HERG serum. Some sections were also
immunolabelled using a polyclonal anti-HERG C-terminus 
antibody, kindly gifted by Dr JM Nerbonne (University of
Washington, St Louis, USA). The nuclear positivity of oestrogen
and progesterone receptors, p53, and cytoplasmic positivity of 
bcl-2, was evaluated by estimating the fraction of positive 
glandular cells on the total number of the glandular cells, in
10 separate fields at   40 HPF. According to Taskin et al (1997),
the immunostaining was scored with 0 (0–5%), 1 (6–10%),
2 (11–50%), 3 (>50%). The cytoplasmic, or rarely nuclear, HERG
immunoreaction was qualitatively scored with + when present,
with – when no immunostaining was recognizable. Sometimes a
focal positivity to anti-HERG antibodies was observed. 
Statistical analysis was performed using the Chi-square, as well
as the Fisher’s test. 
Production of anti-HERG antibodies 
Anti-HERG antibodies were produced by immunizing rabbits with a
fusion protein, representing the highly conserved N-terminal amino
acids of the HERG sequence from 1 to 135 (Li et al, 1997).
Expression of the glutathione S-transferase (GST) fusion protein was
carried out using pGEX-4T-2 vector (Pharmacia). The herg coding
sequence was obtained by amplifying the herg1 cDNA in SP6 vector
(kindly gifted by Dr Keating) using the following primers: 
sense:
GGGTCGACAATGCCGGTGCGGAGG 
antisense:
CAGGCGGCCGCCTACTTCTCCATCACCACC 1724 A Cherubini et al
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A SalI and NotI cutting sequence was inserted in the herg
sequence, so that the PCR product could be ligated in frame in the
pGEX-4T-2 vector; the insert was sequenced to exclude sequence
errors due to the Taq amplification; the N-terminus herg-
containing E. coli (DH5α ) colonies were amplified and the GST
fusion protein purified according to the manufacturer’s protocol;
no cut was applied to eliminate the GST peptide from the fusion
protein. 500 µ g of fusion protein were injected subcutaneously in
adult rabbits along with complete Freund’s adjuvant; two sub-
sequent injections of 250 µ g each were applied, and the level of
specific antibodies was evaluated by an ELISA test. The poly-
clonal antiserum was then aspirated, aliquoted and stored at –80˚C.
The antiserum was tested for its anti-HERG activity in immuno-
blot experiments on membrane extracts obtained from HERG
endowed tissues (see below), and comparing its immunoreactivity
with Dr Nerbonne’s anti-HERG antibody. 
Immunoblot 
Immunoblot with anti-HERG antibodies was performed on a crude
membrane fraction prepared from a mouse brain, essentially
according to Pond et al (2000). Membrane proteins were separated
by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a nitrocellulose sheet. After transfer, membranes
were blocked for 4 h at room temperature with PBS+Tween-20
0.1% containing 5% BSA (T-PBS-BSA) and then incubated
overnight at 4˚C with Dr Nerbonne’s rabbit anti-HERG polyclonal
antibody diluted 1:500 in T-PBS-BSA, or with the raw serum
containing polyclonal anti-HERG antibody obtained in Dr
Arcangeli’s laboratory (see above) diluted 1:5000 in T-PBS-BSA.
Membranes were then washed 3 times with T-PBS and incubated
with anti-rabbit peroxidase-conjugate secondary antibodies
(Sigma; diluited 1:10 000 in T-PBS-BSA) for 1 h at room temper-
ature. After 3 washes with T-PBS, the immunoreactivity was
determined by a chemiluminescent reaction (ECL) (Amersham). 
Reverse transcription (RT) and polymerase chain
reaction (PCR) amplification 
Frozen tissues were homogenized by a guanidinium thiocyanate
solution, and total RNA was extracted using 2 M sodium acetate
pH 4, acid phenol, and chloroform-isoamyl alcohol (49:1). The
aqueous phase, obtained after centrifugation at 15 000 g for
15 min, was precipitated overnight at –20˚C with ethanol. The
pellet was washed twice with 70% ethanol and dissolved in 1 mM
EDTA, 10 mM NaCl, 10 mM Tris-HCl, pH 8.0. RNA purity and
integrity was checked by running an aliquot on a 1% agarose gel
(Maniatis et al, 1989). 1–2 µ g were retrotranscribed in a 20 µ l
reaction by MuLV (Murine Leukaemia Virus Reverse
Transcriptase) (Perkin Elmer) 2.5 U µ l 1, 5 mM MgCl2, 1 mM
d(NTP)s, 1X PCR buffer, RNAse Inhibitor 1 U µ l 1 and 2.5 µ M
random hexamer primers, for 30 min at 42˚C. 5 µ l of cDNA were
then amplified by the polymerase chain reaction in a 50 µ l reaction
containing AmpliTAQ Gold Polymerase 5 U µ l 1 (Perkin Elmer),
2.5 mM MgCl2, 200 µ M d(NTP)s, 1X PCR buffer. The sequence
of ologinucleotide primers was as follows: 
Primer sense:
5′ -TCCAGCGGCTGTACTCGGGC -3′
Primer antisense:
5′ -TGGACCAGAAGTGGTCGGAGAACTC -3′
These primers comprise a sequence between nucleotide 2171 to
nucleotide 2746 of the herg sequence (accession number
HU04270). We carried out 43 cycles of amplification after 10 min
of enzyme activation at 94˚C: denaturation at 94˚C for 1.5 min,
annealing at 65˚C for 3 min, extension at 72˚C for 1.5 min DNA.
Products were run on a 2% agarose gel using a molecular weight
marker, the 100 bp DNA ladder (New England Biolabs) and bands
were visualized by ethidium bromide staining on a UV transillum-
inator. Control amplifications were performed either adding not
retrotranscribed RNA or no-DNA, no-RNA in the PCR tube, but
any aspecific band was never observed. This latter control was
performed every time. 
cDNA samples were checked for integrity by PCR detection of
human  gapdh using AmpliTAQ Polymerase 5 U µ l 1 (Perkin
Elmer), 2 mM MgCl2, 200 µ M d(NTP)s, 1X PCR buffer and the
following primers, which comprise a sequence between nucleotide
457 to nucleotide 595 of gapdh gene: 
Primer sense:
5′ -AACAGCCTCAAGATCATCAGCAA-3′
Primer antisense:
5′ -CAGTCTGGGTGGCAGTGAT-3′
PCR conditions were as follows: denaturation at 94˚C for 1 min,
annealing at 60˚C for 1 min, extention at 72˚C for 1 min, for 
35 cycles. 
A sample of human blood was analysed by RT-PCR amplifica-
tion of herg gene, but any product was never observed, confirming
that blood does not interfere with herg amplification in tissue
samples. The amount of blood used for RNA extraction and sub-
sequent RT-PCR analysis was 50 µ l, considering it the maximum
aliquot of possible contamination of tissue samples, which were
never more than 500 mg in size (10% blood/tissue). 
Sequencing of PCR products 
PCR product obtained after herg amplification in one sample of
adenocarcinoma was submitted to automatic sequencing (MWG-
Biotech GmbH) to confirm the homology between the 575 bp PCR
product and herg gene. 
Patch-clamp recordings 
Patch-clamp recordings were performed on primary cell cultures
obtained from endometrial adenocarcinoma samples, essentially
according to Chatzaki et al (1994). Briefly, hysterectomy speci-
mens were first trimmed and minced, then dissociated through a
first digestion with collagenase II (Roche, 0.05 mg ml 1 final
concentration) at 37˚C for 2 hours, and a second treatment with
trypsin/EDTA solution (0.5 g ml 1 trypsin, 0.2 g ml 1 tetrasodium
EDTA, Sigma) for 10 min at room temperature with constant
agitation. Cells were then washed in complete medium
(Waymouth’s medium supplemented with 10% fetal calf serum
(FCS) (Characterized, Hyclone) and 1% penicillin-streptomycin/
fungizone mixture (Hyclone)), resuspended in the same medium
and seeded into 35 mm Petri dishes (Costar). After 24 hours of
incubation, cell cultures were washed twice with PBS, and fresh
medium was added. The culture medium was then replaced every
two days. 
Patch-clamp recordings were performed at room temperature with
an amplifier Axopatch 1-D (Axon Instruments, Foster City, CA),
replacing the Petri dish every 30 min. The whole cell configurationof the patch clamp technique (Hamill et al, 1981) was employed,
using pipettes (borosilicate glass; Hilgenberg, Germany) whose
resistance was in the range of 3–5 MΩ . Extracellular solutions
were delivered through a 9-hole (0.6 mm), remote-controlled
linear positioner placed near the cell under study. The standard
extracellular solution contained (mM): NaCl 130, KCl 5, CaCl2 2,
Hepes-NaOH 10, glucose 5, pH 7.4. The extracellular solution
with high K+ contained (mM): NaCl 95, KCl 40, CaCl2 2, Hepes-
NaOH 10, glucose 5, pH 7.4. The standard pipette solution at
[Ca2+] = 10–7 M contained (mM): K+ aspartate 130, NaCl 10,
MgCl2 2, CaCl2 2, EGTA-KOH 10, Hepes-KOH 10, pH 7.4.
Gigaseal resistances were in the range of 3–20 GΩ . Whole cell
currents were filtered at 5 kHz. For precise measurement of the
gating parameters of the inward rectifier channels, we carefully
compensated pipette and cell capacitance and the series resistance
before each voltage-clamp protocol run. Input resistance of the
cells was in the range of 2–6 GΩ . The antiarrhythmic drug Way
123,398, kindly gifted by Dr W Spinelli (Wyeth-Ayerst Research,
Princeton, NJ), was used at a 1 µ M concentration, a condition
proved to block HERG currents in cancer cells (Faravelli  et al,
1996). For data acquisition and analysis, the pClamp hardware and
software (Axon Instruments) and Origin (Microcal Software,
Northampton, MA) were routinely used. 
RESULTS 
To study the presence of HERG in primary human tumours, we
analysed the first available specimens belonging to cancerous,
hyperplastic or normal endometria, evaluating the expression of
herg RNA by RT-PCR, amplifying a 575 bp product (Figure 1).
Taking as a control the expression of herg in the human neuro-
blastoma cell line SY5Y (lane 1), the herg RNA resulted to be
expressed in 2 typical human EC (lanes 2 and 3) but not in normal
(lane 4) as well as hyperplastic human endometrium (lane 5). The
PCR amplification band relative to one of the tested adeno-
carcinomas, was purified and submitted to sequencing, resulting
identical to the reported sequence of human herg (Warmke and
Ganetzky, 1994). Other uterine tissues were examined, and a herg
PCR band was found in normal myometrium (lane 6); this finding
led us to exclude from our study all the samples which resulted
contaminated by myometrium at the histological analysis and
all the hypo/atrophic endometrial samples (see Materials and
Methods). On the other hand, a sample of blood, which could
possibly contaminate endometrial samples, gave negative results
(lane 7). Negative controls were also performed on samples
containing not retrotranscribed RNA (lane 8), and no c-DNA no
RNA (lane 9). In Figure 1 results are also reported, referring to a
RT-PCR amplification of the human gapdh gene, taken as an in-
dication of the good quality of the cDNA obtained by retrotran-
scription. As shown in the figure, the gapdh gene resulted positive
in all the samples tested, except in the negative controls (lanes 8
and 9, see legend to Figure 1). 
On the whole, data reported in Figure 1 demonstrated that the
herg RNA can be easily detected in human tissues by a simple 
RT-PCR analysis, and appears to be more frequently expressed 
in human neoplastic tissues as compared to non-cancerous
endometrium. This indication needed to be deepened and con-
firmed by exploring the presence of HERG protein in EC.
Polyclonal anti-HERG antibodies were developed for this purpose
(see Materials and Methods). The immunoreactivity of these anti-
bodies was first tested in immunoblot experiments performed on
membrane extracts obtained from mouse brain, a tissue highly
expressing HERG protein. The immunoreactivity of these anti-
HERG antibodies were compared with that displayed by another
widely used antibody developed in Dr Nerbonne’s laboratory
(Pond et al, 2000). Figure 2 shows the results of this experiment:
two HERG protein bands can be recognized in the mouse brain,
whose molecular weight is about 205 and 165 kDa, either with Dr
Nerbonne’s antibody (lane A), and with the antibody developed in
our laboratory (lane B), according to what was previously reported
(Pond et al, 2000). 
Therefore, the antibody was tested on the adenocarcinomatous
and non-neoplastic tissues previously scored by RT-PCR. SY5Y
neuroblastoma cells and cardiac myocytes were chosen for pos-
itive control in these experiments. Negative control experiments
were also performed with non-immune anti rabbit serum (see
Materials and Methods). As shown in Figure 3 (panel A), SY5Y
HERG expression in human endometrial cancer 1725
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Figure 1 herg RNA expression in normal and tumour tissues. RT-PCR
experiments were performed on SY5Y human neuroblastoma cell line
(positive control, lane 1), EC (lanes 2–3), endometrium (lane 4), endometrial
hyperplasia (lane 5), myometrium (lane 6), blood (lane 7), not
retrotranscribed RNA (negative control, lane 8), and no RNA/no cDNA
samples (negative control, lane 9), with herg and gapdh primers 
(see Material and Methods). 
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Figure 2 Western blot analysis of the HERG protein in mouse brain. Mouse
brain membranes were prepared, separated on SDS-PAGE and transferred
on nitrocellulose sheets as described in Materials and Methods. Membranes
were immunolabelled with a polyclonal anti-HERG C-terminus antibody
produced in Dr Nerbonne’s laboratory (diluted 1:5000, lane A) or with the
anti-HERG N-terminus antibody produced in Dr Arcangeli’s laboratory
(diluted 1:500, lane B). The bands revealed by both antibodies have a
molecular weight of 205 and 165 kDa, according to what was reported by
Pond et al (2000). Molecular weight standards: italic: New England Biolabs;
roman: Biorad. 1726 A Cherubini et al
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cells were positive to anti-HERG antibodies, revealing a prevalent,
diffuse cytoplasmic immunostaining, and only rarely, positive
nuclei; cardiac muscle cells resulted also positive, while the
stromal tissue between muscle fibres was unstained (Figure 3B).
On the other hand, the immunohistochemical picture of a normal
endometrium turned out to be totally negative for the presence of
the HERG protein (Figure 3D). This result appears to be also
strengthened by the fact that the muscle cells of myometrium,
present in the same section, appeared to be strongly positive
(Figure 3C). Adenocarcinomatous tissue (Figure 3G) revealed a
good positivity to anti-HERG antibodies, being however negative
to a non-immune rabbit serum (Figure 3E); the positivity was here
again preferentially localized to the cytoplasm of glandular cells,
while the stroma was totally negative. Here again, a control with
Dr Nerbonne’s antibody is reported, showing a substantially
similar pattern of immunoreactivity (Figure 3F), with a slightly
higher immunolabelling of adenocarcinomatous cell nuclei.
Altogether, data presented in Figure 3 clearly indicate that anti-
HERG antibodies can be useful to detect HERG protein, distin-
guishing tumour endometrial cells from normal endometrium. 
We then investigated whether HERG protein was expressed also
on the plasma membrane of these tumour cells, giving rise to func-
tioning HERG K+ channels. For this reason, patch clamp record-
ings were performed on primary cell cultures obtained from
adenocarcinoma samples, which resulted to be positive at the
immunohistochemical analysis. Figure 4 shows typical current
traces obtained from these cells. After cell perfusion with high K+
solution, to increase the driving force for inward K+ currents at our
test potentials (from +20 to –120 mV), an inward inactivating
current was detected in 70–80% of the tested cells (panel A). 
This current was completely inhibited by the antiarrythmic 
drug Way 123,398 (panel B). In C is reported the IHERG isolated by
substracting the current in presence of Way 123,398 to the 
native current (see also the inset at higher magnification)
(Arcangeli et al, 1995; Sanguinetti et al, 1995; Faravelli et al,
1996). These data indicate that HERG protein, detected in
endometrial cancer cells, is indeed expressed on the cell surface of
these cells, giving rise to HERG channels with normal electro-
physiological features. 
The RT-PCR, as well as the immunohistochemical analysis, were
then performed on further 29 surgical specimens, characterized by
both standard histopathological criteria, and currently used biomol-
ecular markers (estrogen receptors (ER), progesteron receptors
(PgR), p53 and bcl-2 proteins). Data relative to these cases are
reported in Table 1, showing that ER and PgR were diffusely posi-
tive in 17 and 18, respectively, of 18 endometrial adenocarcinoma
and in 9 and 11, respectively, of 11 NCE. Bcl-2 protein was
diffusely expressed in 16 cases of EC (89%) and in 8 NCE (73%).
P53 protein was strongly detected in 13 EC (72%) and in NCE
(27%), although present at lower score in 45% of NCE. 
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Figure 3 Immunohistochemical detection of HERG protein. Anti-HERG N-terminus antibodies, developed as reported in Materials and Methods, were used on
cells cultured in vitro or on paraffin embedded sections, and revealed by immunoperoxidase staining. A clear cytoplasmic immunostaining is evident in 
SY5Y human neuroblastoma cell line (A), myocardic cells (B), glandular adenocarcinomatous cells (G) and myometrial cells (inset, C). Stromal cells 
(in B and C) and glandular cells in a normal secretive endometrium (D), as well as adenocarcinoma cells probed with a non-immune rabbit serum 
(negative control) (E) are completely negative. In F is reported an adenocarcinomatous sample probed with Dr Nerbonne’s anti-HERG antibody. Magnification
was × 400 HPF in A, × 200 HPF in B–F. HERG expression in human endometrial cancer 1727
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The parallel analysis of herg RNA and HERG protein expres-
sion revealed that both are indeed detectable in 67% (12/18) and
82% (14/17), respectively, of cancerous tissues, while are present
at lower percentage (18%) (2/11) in NCE. Interestingly, the only
NCE cases which resulted to be positive to herg/HERG expression
were relative to the secretive stage (see Discussion), while all the
simple endometrial hyperplasia tested resulted negative. 
In tumour cells no significant correlation was found between
herg RNA and HERG protein with age, histological type, grading,
tumour stage or other parameters used (ER, PgR, bcl-2, p53
expression). On the contrary, a significantly higher HERG
expression was found between cancerous versus non-cancerous
endometrium (P = 0.031 (Chi-square test) and P = 0.021 (Fisher’s
test)). An even better statistical result was obtained when
comparing HERG expression in EC versus endometrial hyper-
plasia (P = 0.018 (Chi-square test) and P = 0.014 (Fisher’s test)). 
On the whole, RT-PCR analysis and immunohistochemical
experiments gave substantially similar results, revealing that
cancerous tissues express both herg RNA and HERG protein, the
latter being usually detectable in the cytoplasm of adenocarcinoma
cells. 
DISCUSSION 
K+ channels are evidently involved in the regulation of cell growth
and differentiation of normal (Arcangeli et al, 1997), and cancer
cells in vitro (Arcangeli et al, 1995, 1998, 1999; Faravelli et al,
1996; Bianchi et al, 1998) in particular, the eag family of outward
rectifier K+ channels with its members eag and herg, appears to be
deeply involved in cancinogenesis: in fact, the expression of these
channels seems to be a selective advantage for tumour cells in
vitro (Bianchi et al, 1998; Pardo et al, 1999). However, the pres-
ence and role of such K+ channels in primary human tumours are
still unexplored. We provide here the first demonstration of the
expression of HERG in human primary tumours, showing that the
HERG encoding gene, herg, and its related protein are expressed
in primary endometrial cancers at higher frequency than in non
cancerous endometrium. Moreover, a classical IHERG can be
recorded on the plasma membrane of tumour cells. 
herg RNA expression in EC is easily detectable by RT-PCR tech-
nique, while the HERG protein could be also detected in EC speci-
mens by using specific anti-HERG antibodies, with an even more
selectivity between epithelial tumour cells and glandular normal or
hyperplastic tissue (Figure 3 and Table 1). To this purpose, novel
polyclonal antibodies were developed, whose immunoreactivity
was very similar to that displayed by other widely used anti-HERG
antibodies (Figures 2 and 3). In particular, both herg RNA and
protein were absent in all the simple hyperplasias tested, while they
sometimes resulted positive in some normal endometria. It is
perhaps worth noting that the only two cases of normal
endometrium which turned out positive were both in the secretive
stage, a result that, if confirmed in a larger number of cases, could
somehow hint that HERG is involved in the regulation of secretion
in non-neoplastic endometrial cells, as it is in endocrine cells
(Rosati et al, 1998). At this regard, it is worth noting that the RT-
PCR analysis, performed on a larger number of NCE, gave the
same percentage of positivity, with a selective expression of herg
RNA in some cases of secretive endometrium (not shown). We
want to stress here that, when applied to the same specimens, the
two techniques appeared fairly consistent, stressing that no artifact
or external contamination occur in the detection of both herg RNA
and HERG protein; in fact, only two EC cases, indicated as positive
by the immunohistochemical technique, were scored as negative
with the RT-PCR. In this context, it is important to note that 
some EC displayed only a focal immunostaining, leading to the
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Figure 4 Electrophysiological detection of HERG currents in endometrial
adenocarcinoma cells. Primary cell cultures were obtained from endometrial
adenocarcinoma specimens, as reported in Materials and Methods. Patch
clamp experiments were performed on single cells after 4–5 days of culture.
(A) Traces recorded in extracellular solution containing 40 mM [K+], after
applying the protocol reported on the top of the figure; (B) traces obtained
after addition of Way 123 398 (1 µ M) in the 40 mM [K+] extracellular solution.
(C) Isolated HERG currents obtained after substracting the current in the
presence of Way 123 398 to the native current. Inset: higher magnification of
IHERG reported in C. Top: protocol applied to record HERG traces; holding
potential was 0 mV.1728 A Cherubini et al
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conclusion that the combined use of both techniques could improve
the reliability of HERG as a possible tumour marker. 
Moreover, the comparison of RT-PCR and immunostaining
technique indicates that in normal and neoplastic endometrium
herg expression correlates with the presence of the translated
HERG protein; the latter appears to be particularly abundant in the
cytosol and, only rarely, in the nucleus of epithelial cells. This
distribution of HERG protein is in agreement with that reported by
others in the heart and HERG-transfected cells, using different
antibodies (Babij et al, 1998; Zhou et al, 1998). Moreover, the
great amount of HERG protein in the cytosol of cancer cells could
be explained by the recent discovery that post-translational
defects, such as altered N-glycosylation, which often occurs in
tumour cells (Taylor-Papadimitriou and Epenetos, 1994), can lead
to an intracellular accumulation of HERG protein, with no expres-
sion of the protein on the cell surface (Petrecca et al, 1999). In our
model the only demonstration of HERG protein expression on 
the plasma membrane derives from patch clamp recordings,
performed on endometrial adenocarcinoma cells; such experi-
ments revealed that a normally functioning IHERG is indeed
expressed on the plasma membrane of these cells. This finding
further stresses the role of HERG channels in the mechanism of
regulation of the resting potential of cancer cells (Arcangeli et al,
1995; Olivotto et al, 1996; Bianchi et al, 1998). 
A relevant question to approach in further experiments is also
whether HERG expression in primary EC is one of the genotypic
alterations accompanying tumour progression, or, as in the case of
neuroblastoma (Arcangeli et al, 1998, 1999; Bianchi et al, 1998),
is a crucial aspect of the differentiation block that maintains the
immature phenotype in transformed cells. 
Whatever the merit of these suggestions, our data, showing that
herg and protein are expressed in primary human tumours with a
higher frequency as compared to non-cancerous tissues, could 
also candidate HERG as a possible molecular marker, capable 
of discriminating EC from NCE, in particular from simple
hyperplasia. 
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Table 1 herg RNA and HERG protein expression in primary endometrial carcinomas and normal/hyperplastic endometria. 
Histology Grade Stage ER PgR bcl2 p53 herg HERG 
1. S-AC G1 II A 1 2 1 1 – + 
2. E-AC G1 I B 3 3 3 3 + +* 
3. E-AC G1 I B 3 3 2 3 + + 
4. E-AC G1 N.D. 3 3 3 1 + + 
5. E-AC G2 III C 3 2 0 2 + +* 
6. MES G2 III C 3 3 3 2 – + 
7. E-AC G2 I C 3 3 3 3 + + 
8. E-AC G2 I B 3 3 3 3 + ND 
9. E-AC G2 I C 3 2 2 3 + + 
10. E-AC G2 I C 3 3 3 3 – – 
11. AC-SM G2 III A 3 3 3 2 + +* 
12. E-AC G3 I B 3 3 3 3 + + 
13. E-AC G3 I B 3 3 3 0 – – 
14. E-AC G3 I C 3 3 3 0 – – 
15. AC-SM G3 I C 3 3 3 3 + + 
16. AC-SM G3 I C 3 3 3 0 + + 
17. SP-AC – I B 3 2 2 2 + + 
18. SP-AC – I C 2 2 2 3 – + 
19. PE – – 3 3 2 1 – – 
20. SE – – 0 2 1 0 – – 
21. SE – – 0 2 0 0 + + 
22. SE – – 3 3 3 2 + + 
23. SE – – 2 2 0 0 – – 
24. SEH – – 3 3 3 2 – – 
25. SEH – – 3 3 3 1 – – 
26. SEH – – 3 3 3 0 – – 
27. SEH – – 3 3 3 3 – – 
28. SEH – – 3 3 2 0 – – 
29. SEH – – 3 3 2 0 – – 
Histopathological diagnosis, grading and staging were performed using standard procedures, ER, PgR, p53, bcl-2, and
HERG protein expression were detected by immunohistochemistry, herg mRNA expression was evaluated by RT-PCR.
Surgical specimens relative to human EC (cases 1–18), normal endometrium (cases 19–22) and simple hyperplasia without
atypia (cases 23–29) were analysed. In case No.4 no staging was evaluated since data have been obtained from an
endometrial currettage. S-AC: Secretory adenocarcinoma; E-AC: Endometrioid adenocarcinoma; MES: Mesonephroid or
clear cell adenocarcinoma; AC-SM: Adenocarcinoma with squamous metaplasia; SP-AC: Serous-papillary adenocarcinoma;
PE: Proliferative endometrium; SE: Secretive endometrium; SEH: Simple endometrial hyperplasia without atypia. 
0: ≤ 5%; 1: > 5% ≤ 10%; 2: > 10% ≤ 50%; 3: > 50%. * = Focal expression of HERG protein.HERG expression in human endometrial cancer 1729
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Nazionale delle Ricerche (CNR, Finalized Project ACRO),
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